Sirtex dose sales surge in fiscal Q2

Liver cancer therapy firm Sirtex Medical said that dose sales of its SIR-Spheres microspheres grew 29% in the U.S. for its 2013 fiscal second quarter.

Worldwide, dose sales increased 25% for the period (end-December 31) compared to the 2012 fiscal second quarter. By region, Asia-Pacific dose sales grew 37%, while sales in Europe, the Middle East, and Africa (EMEA) climbed 11%, Sirtex said.

Page 1 of 462
Next Page